

Gerardo Musuraca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113219/publications.pdf>

Version: 2024-02-01

55
papers

1,780
citations

394286

19
h-index

276775

41
g-index

55
all docs

55
docs citations

55
times ranked

2513
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	0.8	268
2	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 59.	3.8	256
3	Role of [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1781-1787.	0.8	160
4	Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. <i>Cancer</i> , 2004, 100, 2190-2194.	2.0	84
5	Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). <i>Lancet Oncology</i> , 2008, 9, 352-358.	5.1	80
6	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , 2007, 92, 771-777.	1.7	74
7	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
8	Extranodal Marginal Zone B-cell Lymphoma of MALT-type of the Lung: Single-center Experience with 12 Patients. <i>Leukemia and Lymphoma</i> , 2003, 44, 821-824.	0.6	67
9	Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 113, 2496-2503.	2.0	66
10	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	1.8	60
11	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
12	Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 291-295.	1.4	44
13	A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. <i>Cancer</i> , 2008, 112, 856-862.	2.0	43
14	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. <i>Haematologica</i> , 2005, 90, 341-7.	1.7	43
15	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	1.7	42
16	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34
17	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
18	Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients. <i>Journal of Translational Medicine</i> , 2018, 16, 172.	1.8	24

#	ARTICLE	IF	CITATIONS
19	IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2015, 13, 229.	1.8	23
20	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	1.3	22
21	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
22	Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. <i>Journal of Medical Virology</i> , 2021, 93, 124-126.	2.5	18
23	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2639.	1.7	17
24	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
25	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	2.0	14
26	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
27	Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. <i>Blood</i> , 2022, 140, 1378-1389.	0.6	14
28	VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. <i>Leukemia and Lymphoma</i> , 2007, 48, 2167-2171.	0.6	11
29	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 548-558.	1.2	10
30	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. <i>Cancers</i> , 2021, 13, 4566.	1.7	10
31	Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1437-1440.	0.6	8
32	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
33	Pentoxifylline-Induced Apoptosis in Chronic Lymphocytic Leukemia: New Insights into Molecular Mechanism. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 287-294.	1.1	8
34	Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms. <i>Journal of Personalized Medicine</i> , 2022, 12, 364.	1.1	8
35	The emerging role of GSK-3 β in the pathobiology of classical Hodgkin lymphoma. <i>Histopathology</i> , 2017, 71, 72-80.	1.6	7
36	Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?. <i>British Journal of Haematology</i> , 2020, 189, 335-338.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	2.4	6
38	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2006, 108, 2431-2431.	0.6	6
39	High-Dose Therapy with Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: The Bologna Experience. <i>Leukemia and Lymphoma</i> , 2004, 45, 321-326.	0.6	5
40	Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. <i>Leukemia and Lymphoma</i> , 2005, 46, 1839-1841.	0.6	5
41	Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). <i>American Journal of Hematology</i> , 2011, 86, 79-80.	2.0	5
42	Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML. <i>Blood Advances</i> , 2020, 4, 5040-5049.	2.5	4
43	Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.. <i>Blood</i> , 2006, 108, 2462-2462.	0.6	4
44	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. <i>Oncology Reports</i> , 2020, 44, 1561-1573.	1.2	4
45	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021, 138, 134-134.	0.6	3
46	Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report. <i>Annals of Hematology</i> , 2015, 94, 1597-1598.	0.8	2
47	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	0.6	2
48	Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?. <i>Medicine (United States)</i> , 2020, 99, e21440.	0.4	1
49	A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 2496-2496.	0.6	1
50	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1
51	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. <i>Blood</i> , 2006, 108, 2478-2478.	0.6	0
52	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
53	Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
54	Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone. <i>Blood</i> , 2020, 136, 18-18.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma. Blood, 2020, 136, 1-1.	0.6	0